We are live on ! Find out more

BrightSpring Health Services

BTSG

Market cap $11.6B

58.73 USD

+0.85

1.47%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

58.73

0.00

0%

1 day

1.47%

5 days

-2.94%

1 month

1.45%

3 months

-6.9%

6 months

42.1%

Year to date

52.94%

1 year

109.82%

5 years

433.91%

10 years

433.91%

About: BrightSpring Health Services Inc is a home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. Its platform delivers clinical services and pharmacy solutions across Medicare, Medicaid, and commercially insured populations. Its segments include Pharmacy Solutions, Provider Services, and others. It generates the majority of its revenue from the Pharmacy Solutions segment.

Employees: 23,500

Healthcare Health Information Services

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 66%

Neutral 29.8%

Negative 4.3%

Zacks Investment Research

BTSG Gains More Than 54% YTD: Should You Buy, Hold or Sell?

BrightSpring Health Services has surged 54% YTD on specialty pharmacy, infusion and EBITDA growth, but premium valuation and policy headwinds remain.

BTSG Gains More Than 54% YTD: Should You Buy, Hold or Sell?

Zacks Investment Research

BTSG's Specialty Pharmacy Sales Up 30%: Will the Growth Continue?

BrightSpring Health Services' Specialty and Infusion sales rose 30%, backed by LDD growth, new launches and expansion into rare therapies.

BTSG's Specialty Pharmacy Sales Up 30%: Will the Growth Continue?

BrightSpring Health Services: 44% Ebitda Growth Is Hard To Ignore

BrightSpring Health Services is rated buy, driven by rapid profitability growth, expanding Provider Services, and reduced financial leverage. In Q2, revenue grew 23% and adjusted EBITDA surged 44%, with management raising 2026 guidance for both revenue and EBITDA. BTSG's premium 34.38x FY1 P/E is justified by strong EBITDA growth and a forward PEG of 0.73x, with multiples declining to 22.19x by FY3.

BrightSpring Health Services: 44% Ebitda Growth Is Hard To Ignore

Zacks Investment Research

Can BTSG Outgrow the $20B Acute Infusion Market on Volume Growth?

BrightSpring Health Services is gaining acute infusion share with 20%+ volume growth, targeting 12-15 new states in a $20 billion market.

Can BTSG Outgrow the $20B Acute Infusion Market on Volume Growth?

Zacks Investment Research

NVIDIA & 2 Profitable Stocks to Buy in September for Big Upside

NVDA's 63.7% net profit margin and 93.3% expected earnings growth put it among three profitable stocks positioned for market volatility.

NVIDIA & 2 Profitable Stocks to Buy in September for Big Upside

Zacks Investment Research

Best Momentum Stocks to Buy for August 26th

BTSG, ANIK and OPHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 26th, 2026.

Best Momentum Stocks to Buy for August 26th

Zacks Investment Research

New Strong Buy Stocks for August 26th

BTSG, OPHC, HRTG, UMC and MTG have been added to the Zacks Rank #1 (Strong Buy) List on August 26th, 2026.

New Strong Buy Stocks for August 26th

Zacks Investment Research

Zacks Industry Outlook CareDx, BrightSpring and PACS

CareDx, BrightSpring and PACS have been highlighted in this Industry Outlook article.

Zacks Industry Outlook CareDx, BrightSpring and PACS

Zacks Investment Research

Sandisk & 2 Profitable Stocks to Buy Now for Explosive Upside

Sandisk, Celestica and BrightSpring rank among profitable stocks, with strong net income ratios and earnings growth supporting upside.

Sandisk & 2 Profitable Stocks to Buy Now for Explosive Upside

Zacks Investment Research

3 Medical Service Stocks Resilient Amid Persistent Workforce Shortage

CareDx, BrightSpring and PACS Group are positioned for growth as digital health expands and workforce shortages reshape medical services.

3 Medical Service Stocks Resilient Amid Persistent Workforce Shortage

See News Rankings

Price charts implemented using Lightweight Charts™